It's over a hundred years since the first case of Alzheimer’s disease was diagnosed. Since then we’ve learned a great deal about the protein ‘tangles’ and ‘plaques’ that cause the disease. How close are we to having effective treatments – and could we even prevent dementia from occurring in the first place?
A specific gene expression pattern maps out which parts of the brain are most vulnerable to Alzheimer’s disease, decades before symptoms appear, and helps define the molecular origins of the disease.
An approved anti-cancer drug successfully targets the first step in the toxic chain reaction that leads to Alzheimer’s disease, suggesting that treatments may be found to lower the risk of developing the neurodegenerative condition.
A molecular chaperone has been found to inhibit a key stage in the development of Alzheimer’s disease and break the toxic chain reaction that leads to the death of brain cells, a new study shows. The research provides an effective basis for searching for candidate molecules that could be used to treat the condition.
Conditions which may accelerate the spread of Parkinson’s disease, and a potential means of enhancing naturally-occurring defences against neurodegenerative disorders, have been identified in two new studies.
The Heineken Prize is among the most prestigious in the scientific community, and a recognition of lifetime achievement which is widely regarded as second only to a Nobel Prize. The award recognises Professor Dobson's achievements in helping to identify the root causes of so-called “modern” disorders, such as Alzheimer’s and Parkinson’s diseases.
What do physicists, chemists, mathematicians and biologists have in common? One of the answers at Cambridge is a shared interest in unravelling the processes behind neurodegenerative diseases such as Alzheimer's, Parkinson's and Motor Neurone Disease.